# Junta clínica — PT-pseudo_562159dc2cc6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_562159dc2cc6",
  "pid": "PT-pseudo_562159dc2cc6",
  "task": 1,
  "psa": 9.9,
  "age": 48,
  "months": 3,
  "pirads": "2",
  "psad": 0.19,
  "psav": 0.31,
  "psap": 6.7,
  "vol": 50.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.6607788,
  "medhx": "Hypertension",
  "meds": "lisinopril, metoprolol",
  "notes": "PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "73 kg",
    "height": "180 cm",
    "bmi": "22.5",
    "bp": "137/81 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (35 pack-yr, quit 2016)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment."
    },
    {
      "s": "History",
      "t": "Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Sleep clinic — suspected obstructive sleep apnoea",
    "Pain clinic — chronic shoulder pain"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_562159dc2cc6
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 48-year-old male
  - PSA: 9.9 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6607788 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.

Vitals: weight 73 kg, height 180 cm, BMI 22.5, BP 137/81 mmHg, HR 81 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2016).

Chief complaint: Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment.

History: Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability.

Physical examination: Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected.

Patient info: retired postal worker; Married; Lives alone; adult daughter is primary contact.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Sleep clinic — suspected obstructive sleep apnoea; Pain clinic — chronic shoulder pain.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.26
  uncertainty  +/- 0.19 epistemic (95% band 0.00-0.63); among patients I cannot tell apart the outcome was 0.83 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 23 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.71: PI-RADS 2, PSA 9.8, PSAD 0.073, age 54, DRE Normal -> DEFER (clear). He wrote: "Young increases importance of longterm risk assessment. BPH, low PSAd, benign MRI, no family history increases confidence to avoid biopsy at this point."
  2. distance 4.29: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"
  3. distance 4.32: PI-RADS 4, PSA 14.0, PSAD 0.734, age 47, DRE Nodus -> BIOPSY (clear). He wrote: "PIRADS 4 with high PSA-density needs biopsy"

PRECEDENT: DEFER (weighted vote 0.22 for biopsy). Distance-weighted precedent is strong here (0.92 leave-one-out).

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 23 labelled traces in this situation (None prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=noted, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that for patients with PI-RADS 2 lesions, omitting biopsy and offering PSA monitoring is recommended when the PSA density is less than 0.20 ng/mL/cc and there is no family history. This is supported by the passage: "Omit biopsy and offer PSA monitoring when MRI is negative (i.e. PI-RADS \u2264 2), and clinical suspicion of PCa is low (PSA density < 0.20 ng/mL/cc and no family history)."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of 'NO BIOPSY' because the guideline requires a specific combination of low PSA density and no family history to support deferral.
EXPERT-COHORT, I disagree with the 'DEFER' conclusion because the cohort criterion is based only on PI-RADS 3 or higher lesions, and this patient has a PI-RADS 2 score, which falls into the deferral category according to the criterion.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: None - the guideline suggests deferral when MRI is negative (PI-RADS \u2264 2) and clinical suspicion is low.
radiology_report - whether the lesion is compared against an earlier study: Unchanged - this fact is relevant as the guideline discusses stable MRI findings.
psa_trend - the PSA trend: PSA velocity of 0.31 ng/mL/yr - this is a variable that the guideline does not explicitly use for the PI-RADS 2 deferral rule.
laboratory_results - the laboratory results: PSA density of 0.19 ng/mL/cc - this value is critical as it is used in the guideline's threshold for deferral.
family-history anamnesis - the family history of prostate cancer: No family history - this is a variable that the guideline explicitly requires for the deferral recommendation.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the low PSA density and lack of family history, as per the EAU guideline, are sufficient to defer biopsy despite the PI-RADS 2 finding.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone information support the PI-RADS 2 assessment?
  psa_trend (get_psa_trend) -> How does the PSA velocity of 0.31 ng/mL/yr influence the decision?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy status?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the GRADE of the prior biopsy status?
  Q2. What is the PSA velocity of 0.31 ng/mL/yr, and how does this factor into the decision?

On the plan itself: The moderator asked for laboratory_results, which the reading urologist does not open in this situation; dropped — every reveal beyond his is scored against us. Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PI-RADS 2 score, combined with the PSA density of 0.19 ng/mL/cc and no family history, meet the EAU criteria for deferral?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: Benign prostatic enlargement measuring 50.0 mL. No PI-RADS 3 or higher lesion identified. PI-RADS 2.

psa_trend
The PSA velocity of 0.31 ng/mL/yr is derived from the trend: PSA 2.9 (Feb 2024) rising to 9.9 (Jan 2025), with a rate of increase over the period.

previous_notes
PRIOR GRADE: None
BIOPSY SESSIONS: None
SURVEILLANCE: MRI scans and updated chemistry panel have been dispatched for specialist assessment.
TREATMENT: None recorded

WHAT I DID NOT OPEN
laboratory_results, because the decision hinges on the EAU criteria which are partially covered by the other documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
PSA density of 0.19 ng/mL/cc meets the EAU threshold for deferral.
No family history is noted, which is a requirement for deferral according to the guideline.

AGAINST sampling this patient now
PSA velocity of 0.31 ng/mL/yr suggests a concerning trajectory.

WHERE THIS LEANS
The EAU guideline strongly supports deferral given the PI-RADS 2 score, low PSA density, and no family history.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 9.90 ng/mL over 3 points spanning 11 months; velocity +7.52 ng/mL per year; doubling time about 6 months.
PROJECTION at 6 months: 16.0 ng/mL, conformal 95% band 4.6-55.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.20
  uncertainty  +/- 0.14 epistemic (95% band 0.00-0.47), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.26  ('supports' tier; weight 2.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.20  ('firm' tier, fusion_nolab; weight 4.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.22  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule pirads_le_2; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (pirads_le_2) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 24 of 24 labelled cases in exactly this situation (never biopsied).

Confidence the trace model expects here: clear. Weights it expects: bx=noted, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—address the moderator's questions regarding the prior biopsy status and PSA velocity.

ALIGNMENT WITH THE PANEL
The retrieved evidence aligns with the PANEL-PROTOCOL's answer of NO BIOPSY, as the registrar found "PRIOR GRADE: None" in the previous_notes, which supports the cohort criterion firing.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the GRADE of the prior biopsy status? The registrar reported "PRIOR GRADE: None" in the previous_notes.
Q2. What is the PSA velocity of 0.31 ng/mL/yr, and how does this factor into the decision? The registrar reported the velocity as "0.31 ng/mL/yr" in the psa_trend.

WHAT CARRIES WEIGHT, AND WHY
The PSA velocity (0.31 ng/mL/yr) is relevant because the registrar noted it suggests a concerning trajectory against the guideline's deferral criteria. The prior biopsy status (None) is critical as it is a key variable weighted by the trace model.

MY SUGGESTION TO THE CHAIR
The EAU guideline strongly supports deferral given the PI-RADS 2 score, low PSA density, and no family history, which are all supported by the retrieved data. The rising PSA velocity is a counterpoint but does not overturn the guideline-based deferral recommendation.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Age 48, PSA 9.9 ng/mL, PSAD 0.19, PI-RADS 2, biopsy-naive. Defer biopsy as PI-RADS 2 with low PSAD (<0.20) warrants PSA monitoring. Re-check PSA and biopsy only if it continues to rise.

What carried weight: bx=noted, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
